PEOPLE - Stelex makes appointment:
This article was originally published in Clinica
Strategic business management specialist Michael Khavinson has been named president of Vital Signs' compliance and solutions subsidiary Stelex (Bensalem, Pennsylvania). He said: "Our goal is to become the most respected consulting firm in the regulated market, serving pharma, devices, diagnostics and biotech companies."
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.